A selection of blockbuster announcements
1、$Xiansheng Pharmaceutical Co., Ltd. (02096.HK) $The world's first subcutaneous injection of PD-L1 antibody Envoli monoclonal antibody injection has been approved for sale in China.
Xiansheng Pharmaceutical announced that on November 25, 2021 The group cooperates with Siludi (Beijing) Pharmaceutical Technology Co., Ltd. ("Siludi (Beijing) Pharmaceutical") and Jiangsu Kangning Jerry Biopharmaceutical Co., Ltd. ("Jiangsu Corning Jerry"). The recombinant humanized PD-L1 single-domain antibody Fc fusion protein injection (common name: Envoli monoclonal antibody injection) has been conditionally approved by the State Drug Administration ("NMPA") to be listed in China. It is suitable for the treatment of unresectable or metastatic microsatellite highly unstable (MSI-H) or mismatch repair gene deficiency (dMMR) adult advanced solid tumors, including advanced colorectal cancer patients who have progressed after previous treatment with fluorouracil, oxaliplatin and irinotecan, as well as other advanced solid tumors who have progressed after previous treatment and have no satisfactory alternative treatment.
2、$minimally invasive robot-B (02252.HK) $R-One vascular interventional surgery robot completes NMPA registration clinical trial: the first case in the group
Minimally invasive robot announcement, the company and the French Robocath S.A.S joint venture Zhimai (Shanghai) Robot Co., Ltd. (hereinafter referred to as "Zhimai") introduced R-One vascular interventional surgery robot to complete the first robot-assisted percutaneous coronary intervention in China. This is the first enrollment of a clinical trial registered by the State Drug Administration ("NMPA") completed by R-One drugs and marks a new milestone for the company in the vascular intervention industry.
3、$China Merchants Bank (03968.HK) $Approved to issue open-ended capital bonds of not more than 43 billion yuan
China Merchants Bank issued an announcement, China Merchants Bank has received the approval of the China Banking and Insurance Regulatory Commission on China Merchants Bank's issuance of open-ended capital bonds (Bancassurance Supervision reply (2021) No. 838) and the decision of the people's Bank of China to grant administrative license (Bank of China grant decision (2021) No. 184). It is agreed that the company will issue no more than 43 billion yuan of open-ended capital bonds in the national interbank bond market.
4、$Bosideng International (03998.HK) $Medium-term revenue increased by 15.6% year-on-year to 5.389 billion
Bosideng International announced that in the six months ended September 30, 2021, the company's revenue increased by 15.6% to about RMB 5.39 billion, gross profit margin increased by 2.7% to 50.5%, and operating profit increased by 0.5% to 14.8%. The profit attributable to the company's equity shareholders rose by 31.4% to about 640 million yuan, and the board of directors declared an interim dividend of HK4.5 cents per common share. During the period, the brand down jacket business remained the largest source of income for the group, with revenue of about 3.473 billion yuan, accounting for 64.5% of the total income, up 16.2% from the same period last year. The income recorded by the OEM processing management business was about 1.428 billion yuan, accounting for 26.5% of the total income, an increase of 16.2% over the same period last year. The diversified clothing business recorded revenue of about 71.8 million yuan, accounting for 1.3% of the total revenue, up 129.2% from a year earlier.
5、BABA Pictures (01060.HK) $In the first half of the year, the camp realized 1.358 billion yuan, and the adjusted EBITA was a loss of about 5 million yuan.
BABA Pictures announced interim results for the six months ended September, with revenue of 1.358 billion yuan in the first half (the same below), an annual increase of 46.6 percent. The loss per share was 0.2 yuan in the first half of the year and 0.61 yuan in the same period last year. The adjusted EBITA for the first half of the year is about RMB 5 million, which is close to the break-even point. Compared with the previous period, the loss is about RMB 104 million, and the loss is significantly narrowed by nearly RMB 100m. No interim interest.
6、In the mood for the year Holdings (01777.HK) $The subsidiary company in the mood for investment was applied for winding up due to loan problems
On November 24th, the principal subsidiary of the Company was filed for winding-up petition relating to the alleged outstanding principal of US $149 million loan financing, with pattern year Investment as the guarantor. The company will seek legal advice to safeguard its legitimate rights and interests and take all necessary measures to resolve the matter, including a constructive dialogue with the petitioner. Our company will issue a further announcement in due course.
Trend of new shares
Minimally invasive Robot-B (02252): price stabilization action and end of price stabilization period
Pattern year Holdings (01777): the subsidiary's pattern year Investment is applied for winding up due to loan problems.
Cosco Marine Port (01199): China Merchants Port and other parties signed joint venture agreements and articles of association
China Communications Construction (01800): four subsidiaries plan to carry out debt-to-equity swap business by increasing capital, expanding shares and repaying debts, bringing in investors with a total capital increase of no more than 7.5 billion yuan.
China Communications Construction (01800): China Communications and Construction Liberia Co., Ltd., a wholly-owned subsidiary to be established.
China Gas (00384): enter into a strategic cooperation agreement with Victoria Group to jointly expand China's LNG trade market.
Minimally invasive Robot-B (02252): the first robot-assisted percutaneous coronary intervention (PCI) in China was completed with the introduction of a joint venture R-One vessel interventional surgery robot.
Yasheng Pharmaceutical-B (06855): the original Class 1 new drug Orebatinib tablets is officially approved by the State Drug Administration (NMPA) of China.
Corning Jerry Pharmaceutical-B (09966): KN035 (Envoli Monoclonal Antibody injection) is approved by the State Drug Administration for listing in China.
Xiansheng Pharmaceutical (02096): KN035 (Envoli Monoclonal Antibody injection) is approved by the State Drug Administration for listing in China.
Sihuan Medicine (00460): Xuan bamboo biological pyrrosinil (combined with aromatase inhibitor) is approved to conduct phase III clinical trials
Shanghai Pharmaceutical (02607): evaluation of the consistency of clozapine tablets through generic drugs
Shandong Xinhua Pharmaceutical Co., Ltd. (00719): 2021 A-share Stock option incentive Plan approved by Hualu Holdings
INNOVENT BIO (01801): Nerek ®is officially approved by the State Drug Administration for the treatment of chronic myeloid leukemia.
Clover bio-B _ (02197): COVID-19 candidate vaccine is administered as a heterologous enhancer in phase II clinical trials led by researchers.
Financial report data
Li Da Pharmaceutical Co., Ltd. (00950): net profit in the first three quarters was HK $2.169 billion, an increase of 1677.8% over the same period last year.
BABA Pictures (01060): medium-term income increased by 47% to 1.358 billion yuan
Bosideng International (03998): medium-term profit attributable to shareholders increased by 31.4% to about 638.5 million yuan, or HK4.5 cents per share
Beijing Control Clean Energy Group (01250): generating capacity of about 359600 MW hours was completed in October, an increase of 13.8% over the same period last year.
Corning Jerry Pharmaceutical-B (09966): awarded 1.1134 million award shares on November 25th
HSBC Holdings PLC (00005): buy back 1.5528 million shares on November 24th
HSBC Holdings PLC (00005): buy back 3.8814 million shares on November 25th
Edit / irisz